Login / Signup

Can we go for a shorter treatment course in chronic hepatitis C? More inspiring cases.

Rosa ZampinoMartina VitroneAntonio ParrellaEnrico RagoneEmanuele Durante-Mangoni
Published in: Journal of chemotherapy (Florence, Italy) (2017)
Current interest in HCV therapy with direct acting antivirals is focused on shortening treatment length. We managed two cirrhotics who achieved virological cure after 4 weeks of ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin treatment. Analysis to identify potential predictive factors for a successful outcome with a shorter treatment course was conducted.
Keyphrases
  • hepatitis c virus
  • stem cells
  • human immunodeficiency virus
  • bone marrow
  • hiv infected patients